Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CLEO Diagnostics Ltd ( (AU:COV) ).
Cleo Diagnostics Ltd has issued 8,362,084 new fully paid ordinary shares without a disclosure document under the relevant fundraising provisions of the Corporations Act 2001, relying on its status as a compliant listed entity. The company confirmed it remains up to date with its financial reporting and continuous disclosure obligations and that there is no excluded information requiring disclosure, signalling regulatory compliance and transparency around the capital issuance for existing and prospective shareholders.
The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd (ASX: COV) is an Australian-listed company in the healthcare and diagnostics sector, focused on developing and commercialising diagnostic solutions, with its operations based in Melbourne, Victoria.
Average Trading Volume: 255,151
Technical Sentiment Signal: Buy
Current Market Cap: A$80.95M
Find detailed analytics on COV stock on TipRanks’ Stock Analysis page.